10x Genomics (TXG) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

TXG Stock Forecast

10x Genomics stock forecast is as follows: an average price target of $46.00 (represents a 209.97% upside from TXG’s last price of $14.84) and a rating consensus of 'Hold', based on 9 wall street analysts offering a 1-year stock forecast.

TXG Price Target

The average price target for 10x Genomics (TXG) is $46.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $46.00 to $46.00. This represents a potential 209.97% upside from TXG's last price of $14.84.

TXG Analyst Ratings

Hold

According to 9 Wall Street analysts, 10x Genomics's rating consensus is 'Hold'. The analyst rating breakdown for TXG stock is 0 'Strong Buy' (0.00%), 3 'Buy' (33.33%), 5 'Hold' (55.56%), 1 'Sell' (11.11%), and 0 'Strong Sell' (0.00%).

10x Genomics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 13, 2024	Tejas Savant	Morgan Stanley	$46.00	$19.65	134.10%	209.97%
Jul 23, 2024	Kyle Mikson	Canaccord Genuity	$32.00	$18.11	76.70%	115.63%
Jul 10, 2024	Justin Bowers	Deutsche Bank	$25.00	$18.25	36.99%	68.46%
Jun 28, 2024	Luke Sergott	Barclays	$24.00	$19.85	20.91%	61.73%
Jun 03, 2024	Tycho Peterson	Jefferies	$24.00	$22.42	7.05%	61.73%
May 01, 2024	Luke Sergott	Barclays	$36.00	$29.28	22.95%	142.59%
Apr 10, 2024	Luke Sergott	Barclays	$45.00	$37.37	20.42%	203.23%
Dec 14, 2022		Deutsche Bank	$50.00	$35.21	42.01%	236.93%

The latest 10x Genomics stock forecast, released on Aug 13, 2024 by Tejas Savant from Morgan Stanley, set a price target of $46.00, which represents a 134.10% increase from the stock price at the time of the forecast ($19.65), and a 209.97% increase from TXG last price ($14.84).

10x Genomics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	7
Avg Price Target	-	-	$33.14
Last Closing Price	$14.84	$14.84	$14.84
Upside/Downside	-100.00%	-100.00%	123.32%

In the current month, the average price target of 10x Genomics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to 10x Genomics's last price of $14.84. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 30, 2024	UBS	Neutral	Neutral	Hold
Oct 30, 2024	Goldman Sachs	Sell	Sell	Hold
Oct 30, 2024	Citigroup	Buy	Buy	Hold
Oct 16, 2024	Cowen & Co.	Hold	Hold	Hold
Oct 10, 2024	UBS	Buy	Buy	Hold
Oct 10, 2024	Stephens	Underperform	Underperform	Hold
Sep 03, 2024	UBS	Buy	Buy	Hold
Aug 13, 2024	UBS	Buy	Buy	Hold
Aug 13, 2024	Jefferies	Underperform	Underperform	Hold
Jul 22, 2024	Jefferies	Hold	Buy	Upgrade
Jul 10, 2024	Deutsche Bank	Buy	Hold	Downgrade
Jun 28, 2024	Barclays	Overweight	Overweight	Hold
Jun 27, 2024	Wolfe Research		Peer Perform	Downgrade
Jun 25, 2024	Guggenheim		Neutral	Downgrade
Jun 03, 2024	Jefferies		Hold	Initialise
May 01, 2024	Cowen & Co.		Hold	Downgrade
May 01, 2024	Barclays	Overweight	Overweight	Hold
Mar 26, 2024	CFRA		Buy	Upgrade
Dec 12, 2023	Bank of America Securities		Neutral	Upgrade
Dec 14, 2022	Deutsche Bank		Buy	Initialise
Aug 18, 2022	Goldman Sachs		Neutral	Downgrade

10x Genomics's last stock rating was published by UBS on Oct 30, 2024. The company gave TXG a "Neutral" rating, the same as its previous rate.

10x Genomics Financial Forecast

10x Genomics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$153.64M	$146.82M	$134.28M	$156.23M	$131.07M	$114.61M	$114.50M	$143.53M	$125.30M	$115.84M	$105.82M	$112.22M	$71.82M	$42.91M	$71.91M	$75.29M	$61.21M
Avg Forecast	$177.75M	$168.23M	$160.08M	$144.56M	$173.76M	$160.45M	$151.86M	$141.81M	$158.72M	$156.89M	$150.08M	$142.24M	$182.73M	$151.30M	$139.97M	$128.82M	$148.17M	$128.96M	$115.70M	$113.25M	$148.53M	$122.56M	$112.85M	$102.51M	$100.40M	$61.19M	$32.56M	$73.42M	$70.00M	$54.90M
High Forecast	$192.18M	$181.89M	$173.08M	$156.30M	$187.87M	$173.48M	$164.19M	$151.90M	$165.60M	$159.89M	$150.08M	$142.24M	$182.80M	$155.34M	$151.33M	$139.28M	$155.99M	$128.96M	$115.70M	$113.25M	$148.53M	$122.56M	$112.85M	$102.51M	$100.40M	$61.19M	$32.56M	$73.42M	$70.00M	$54.90M
Low Forecast	$169.10M	$160.04M	$152.29M	$137.52M	$165.30M	$152.64M	$144.47M	$134.48M	$152.55M	$153.90M	$150.08M	$142.24M	$182.60M	$142.24M	$133.15M	$122.55M	$143.59M	$128.96M	$115.70M	$113.25M	$148.53M	$122.56M	$112.85M	$102.51M	$100.40M	$61.19M	$32.56M	$73.42M	$70.00M	$54.90M
# Analysts	6	4	4	6	4	3	7	9	7	3	1	1	3	10	9	9	8	8	8	8	9	9	9	9	9	9	9	9	8	8
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.02%	1.05%	1.04%	1.05%	1.02%	0.99%	1.01%	0.97%	1.02%	1.03%	1.03%	1.12%	1.17%	1.32%	0.98%	1.08%	1.11%

10x Genomics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $182.73M, with a low forecast of $182.60M, and a high forecast of $182.80M. TXG's average Quarter revenue forecast represents a 18.93% increase compared to the company's last Quarter revenue of $153.64M (Sep 23).

10x Genomics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	6	4	4	6	4	3	7	9	7	3	1	1	3	10	9	9	8	8	8	8	9	9	9	9	9	9	9	9	8	8
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-94.80M	$-63.36M	$-49.63M	$-16.29M	$-39.92M	$-63.72M	$-41.57M	$-8.45M	$-9.15M	$-2.56M	$-4.43M	$-402.89M	$-59.99M	$-34.97M	$-15.92M	$-3.19M	$-6.85M
Avg Forecast	$-60.98M	$-57.72M	$-54.92M	$-49.60M	$-59.62M	$-55.05M	$-52.10M	$-48.65M	$-54.45M	$-53.83M	$-51.49M	$-44.78M	$-62.69M	$-51.91M	$-48.02M	$-40.71M	$-6.20M	$-27.37M	$-24.55M	$-32.18M	$-31.52M	$-26.01M	$-23.95M	$-6.35M	$-21.31M	$-12.98M	$-6.91M	$-10.94M	$-14.85M	$-5.13M
High Forecast	$-58.01M	$-54.91M	$-52.25M	$-47.18M	$-56.71M	$-52.37M	$-49.56M	$-46.14M	$-52.34M	$-52.80M	$-51.49M	$-35.82M	$-62.65M	$-48.80M	$-45.68M	$-32.57M	$-4.96M	$-27.37M	$-24.55M	$-25.74M	$-31.52M	$-26.01M	$-23.95M	$-5.08M	$-21.31M	$-12.98M	$-6.91M	$-8.75M	$-14.85M	$-4.11M
Low Forecast	$-65.93M	$-62.40M	$-59.38M	$-53.62M	$-64.45M	$-59.52M	$-56.33M	$-52.11M	$-56.81M	$-54.85M	$-51.49M	$-53.73M	$-62.72M	$-53.30M	$-51.92M	$-48.85M	$-7.44M	$-27.37M	$-24.55M	$-38.62M	$-31.52M	$-26.01M	$-23.95M	$-7.61M	$-21.31M	$-12.98M	$-6.91M	$-13.12M	$-14.85M	$-6.16M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.83%	1.32%	1.22%	2.63%	1.46%	2.60%	1.29%	0.27%	0.35%	0.11%	0.70%	18.91%	4.62%	5.06%	1.46%	0.21%	1.33%

undefined analysts predict TXG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than 10x Genomics's previous annual EBITDA (undefined) of $NaN.

10x Genomics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	6	4	4	6	4	3	7	9	7	3	1	1	3	10	9	9	8	8	8	8	9	9	9	9	9	9	9	9	8	8
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-92.99M	$-62.41M	$-50.75M	$-17.21M	$-41.91M	$-64.46M	$-42.41M	$-18.45M	$-17.17M	$-11.05M	$-11.55M	$-415.57M	$-65.85M	$-40.17M	$-21.14M	$-7.13M	$-9.60M
Avg Forecast	$-27.42M	$-31.46M	$-38.68M	$-51.61M	$-29.71M	$-33.62M	$-40.57M	$-48.28M	$-35.91M	$-39.68M	$-57.83M	$-45.69M	$-42.17M	$-55.59M	$-48.24M	$-41.54M	$-13.53M	$-56.05M	$-46.56M	$-32.84M	$-10.37M	$-22.69M	$-31.25M	$-16.56M	$-22.79M	$-36.59M	$-59.79M	$-14.52M	$-15.68M	$-7.20M
High Forecast	$-25.69M	$-29.47M	$-36.23M	$-48.35M	$-27.83M	$-31.49M	$-38.00M	$-37.55M	$-29.18M	$-37.17M	$-54.17M	$-36.55M	$-25.77M	$-38.67M	$-45.18M	$-33.23M	$-10.82M	$-56.05M	$-46.56M	$-26.27M	$-10.37M	$-22.69M	$-31.25M	$-13.25M	$-22.79M	$-36.59M	$-59.79M	$-11.62M	$-15.68M	$-5.76M
Low Forecast	$-30.32M	$-34.78M	$-42.76M	$-57.06M	$-32.85M	$-37.16M	$-44.85M	$-56.32M	$-39.28M	$-43.87M	$-63.94M	$-54.83M	$-57.40M	$-70.09M	$-53.33M	$-49.84M	$-16.24M	$-56.05M	$-46.56M	$-39.40M	$-10.37M	$-22.69M	$-31.25M	$-19.87M	$-22.79M	$-36.59M	$-59.79M	$-17.43M	$-15.68M	$-8.64M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.67%	1.29%	1.22%	1.27%	0.75%	1.38%	1.29%	1.78%	0.76%	0.35%	0.70%	18.24%	1.80%	0.67%	1.46%	0.45%	1.33%

10x Genomics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TXG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

10x Genomics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	6	4	4	6	4	3	7	9	7	3	1	1	3	10	9	9	8	8	8	8	9	9	9	9	9	9	9	9	8	8
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$82.42M	$91.51M	$83.28M	$78.89M	$73.40M	$79.34M	$66.67M	$69.88M	$62.08M	$68.70M	$56.90M	$55.97M	$51.55M	$44.42M	$50.39M	$38.76M	$32.61M
Avg Forecast	$101.91M	$96.46M	$91.78M	$82.89M	$99.63M	$92.00M	$87.07M	$81.31M	$91.00M	$89.96M	$86.05M	$71.83M	$104.77M	$86.75M	$80.25M	$65.30M	$51.24M	$73.84M	$66.25M	$51.62M	$85.04M	$70.17M	$64.61M	$81.56M	$57.48M	$35.03M	$18.64M	$34.61M	$40.08M	$24.46M
High Forecast	$110.19M	$104.29M	$99.23M	$89.61M	$107.72M	$99.46M	$94.14M	$87.09M	$94.95M	$91.67M	$86.05M	$86.19M	$104.81M	$89.07M	$86.77M	$78.36M	$61.49M	$73.84M	$66.25M	$61.94M	$85.04M	$70.17M	$64.61M	$97.87M	$57.48M	$35.03M	$18.64M	$41.53M	$40.08M	$29.35M
Low Forecast	$96.95M	$91.76M	$87.31M	$78.85M	$94.78M	$87.52M	$82.83M	$77.10M	$87.47M	$88.24M	$86.05M	$57.46M	$104.70M	$81.55M	$76.34M	$52.24M	$40.99M	$73.84M	$66.25M	$41.30M	$85.04M	$70.17M	$64.61M	$65.25M	$57.48M	$35.03M	$18.64M	$27.69M	$40.08M	$19.57M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.95%	1.14%	1.28%	1.54%	0.99%	1.20%	1.29%	0.82%	0.88%	1.06%	0.70%	0.97%	1.47%	2.38%	1.46%	0.97%	1.33%

10x Genomics's average Quarter SG&A projection for Dec 23 is $104.77M, based on 3 Wall Street analysts, with a range of $104.70M to $104.81M. The forecast indicates a 27.12% rise compared to TXG last annual SG&A of $82.42M (Sep 23).

10x Genomics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	6	4	4	6	4	3	7	9	7	3	1	1	3	10	9	9	8	8	8	8	9	9	9	9	9	9	9	9	8	8
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.79	$-0.53	$-0.44	$-0.15	$-0.37	$-0.57	$-0.38	$-0.16	$-0.15	$-0.10	$-0.11	$-3.87	$-0.65	$-0.41	$-0.22	$-0.07	$-0.33
Avg Forecast	$-0.23	$-0.26	$-0.32	$-0.43	$-0.25	$-0.28	$-0.34	$-0.40	$-0.30	$-0.33	$-0.48	$-0.50	$-0.35	$-0.46	$-0.40	$-0.37	$-0.28	$-0.47	$-0.39	$-0.34	$-0.09	$-0.19	$-0.26	$-0.27	$-0.19	$-0.30	$-0.50	$-0.13	$-0.13	$-0.13
High Forecast	$-0.21	$-0.24	$-0.30	$-0.40	$-0.23	$-0.26	$-0.31	$-0.31	$-0.24	$-0.31	$-0.45	$-0.47	$-0.21	$-0.32	$-0.37	$-0.35	$-0.27	$-0.47	$-0.39	$-0.34	$-0.09	$-0.19	$-0.26	$-0.27	$-0.19	$-0.30	$-0.50	$-0.13	$-0.13	$-0.13
Low Forecast	$-0.25	$-0.29	$-0.35	$-0.47	$-0.27	$-0.31	$-0.37	$-0.47	$-0.33	$-0.36	$-0.53	$-0.55	$-0.48	$-0.58	$-0.44	$-0.41	$-0.30	$-0.47	$-0.39	$-0.34	$-0.09	$-0.19	$-0.26	$-0.27	$-0.19	$-0.30	$-0.50	$-0.13	$-0.13	$-0.13
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.72%	1.33%	1.18%	0.54%	0.79%	1.47%	1.13%	1.85%	0.79%	0.38%	0.40%	20.39%	2.13%	0.82%	1.66%	0.54%	2.63%

According to undefined Wall Street analysts, 10x Genomics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TXG previous annual EPS of $NaN (undefined).

10x Genomics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
FATE	Fate Therapeutics	$1.31	$5.00	281.68%	Buy
TXG	10x Genomics	$14.84	$46.00	209.97%	Hold
BEAM	Beam Therapeutics	$25.91	$50.50	94.91%	Buy
TWST	Twist Bioscience	$49.52	$46.00	-7.11%	Buy
GH	Guardant Health	$47.65	$39.00	-18.15%	Buy
VCYT	Veracyte	$44.44	$35.00	-21.24%	Buy

TXG Forecast FAQ

Is 10x Genomics a good buy?

No, according to 9 Wall Street analysts, 10x Genomics (TXG) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 33.33% of TXG's total ratings.

What is TXG's price target?

10x Genomics (TXG) average price target is $46 with a range of $46 to $46, implying a 209.97% from its last price of $14.84. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will 10x Genomics stock go up soon?

According to Wall Street analysts' prediction for TXG stock, the company can go up by 209.97% (from the last price of $14.84 to the average price target of $46), up by 209.97% based on the highest stock price target, and up by 209.97% based on the lowest stock price target.

Can 10x Genomics stock reach $20?

TXG's average twelve months analyst stock price target of $46 supports the claim that 10x Genomics can reach $20 in the near future.

What are 10x Genomics's analysts' financial forecasts?

10x Genomics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $627.89M (high $677.44M, low $596.89M), average EBITDA is $-215M (high $-205M, low $-232M), average net income is $-152M (high $-135M, low $-171M), average SG&A $360M (high $388.41M, low $342.23M), and average EPS is $-1.26 (high $-1.117, low $-1.418). TXG's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $650.63M (high $703.44M, low $618.95M), average EBITDA is $-223M (high $-212M, low $-241M), average net income is $-149M (high $-140M, low $-165M), average SG&A $373.04M (high $403.32M, low $354.87M), and average EPS is $-1.236 (high $-1.157, low $-1.366).

Did the TXG's actual financial results beat the analysts' financial forecasts?

Based on 10x Genomics's last annual report (Dec 2022), the company's revenue was $516.41M, beating the average analysts forecast of $506.09M by 2.04%. Apple's EBITDA was $-161M, beating the average prediction of $-90.3M by 78.84%. The company's net income was $-166M, beating the average estimation of $-149M by 11.43%. Apple's SG&A was $298.3M, beating the average forecast of $242.95M by 22.78%. Lastly, the company's EPS was $-1.46, missing the average prediction of $-1.468 by -0.58%. In terms of the last quarterly report (Sep 2023), 10x Genomics's revenue was $153.64M, beating the average analysts' forecast of $151.3M by 1.55%. The company's EBITDA was $-94.795M, beating the average prediction of $-51.909M by 82.62%. 10x Genomics's net income was $-92.986M, beating the average estimation of $-55.587M by 67.28%. The company's SG&A was $82.42M, missing the average forecast of $86.75M by -5.00%. Lastly, the company's EPS was $-0.79, beating the average prediction of $-0.46 by 71.59%